Journal articles on the topic 'Vaccines industry Australia'
To see the other types of publications on this topic, follow the link: Vaccines industry Australia.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Vaccines industry Australia.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Grohmann, Gary. "Regulatory issues in pandemic influenza vaccine development." Microbiology Australia 27, no. 4 (2006): 172. http://dx.doi.org/10.1071/ma06172.
Full textAbstract:
The Therapeutic Goods Administration (TGA) is responsible for the licensing of vaccines used in Australia. This includes pre-market evaluation aspects (such as assessing the quality, efficacy and safety of vaccines) and post-market aspects (such as batch release testing and the monitoring of adverse reactions). For inter-pandemic and pandemic influenza vaccines, TGA is also involved in the selection of appropriate vaccine viruses and the calibration and supply of reagents for the production of influenza vaccines. Together with industry, TGA has a responsibility to ensure that all regulatory and good manufacturing requirements (GMP) are met to ensure vaccine safety and efficacy.
2
Rawlinson, Paddy. "Immunity and Impunity: Corruption in the State-Pharma Nexus." International Journal for Crime, Justice and Social Democracy 6, no. 4 (November 14, 2017): 86–99. http://dx.doi.org/10.5204/ijcjsd.v6i4.447.
Full textAbstract:
Critical criminology repeatedly has drawn attention to the state-corporate nexus as a site of corruption and other forms of criminality, a scenario exacerbated by the intensification of neoliberalism in areas such as health. The state-pharmaceutical relationship, which increasingly influences health policy, is no exception. That is especially so when pharmaceutical products such as vaccines, a burgeoning sector of the industry, are mandated in direct violation of the principle of informed consent. Such policies have provoked suspicion and dissent as critics question the integrity of the state-pharma alliance and its impact on vaccine safety. However, rather than encouraging open debate, draconian modes of governance have been implemented to repress and silence any form of criticism, thereby protecting the activities of the state and pharmaceutical industry from independent scrutiny. The article examines this relationship in the context of recent legislation in Australia to intensify its mandatory regime around vaccines. It argues that attempts to undermine freedom of speech, and to systematically excoriate those who criticise or dissent from mandatory vaccine programs, function as a corrupting process and, by extension, serve to provoke the notion that corruption does indeed exist within the state-pharma alliance.
3
Kaufman, Jessica, Isabella Overmars, Julie Leask, Holly Seale, Melanie Chisholm, Jade Hart, Kylie Jenkins, and Margie Danchin. "Vaccine Champions Training Program: Empowering Community Leaders to Advocate for COVID-19 Vaccines." Vaccines 10, no. 11 (November 9, 2022): 1893. http://dx.doi.org/10.3390/vaccines10111893.
Full textAbstract:
Strong community engagement has been critical to support COVID-19 vaccine uptake in Australia and elsewhere. Community engagement builds trust, enables tailored information dissemination and shapes social norms. Engagement is particularly important in communities with greater vaccine hesitancy, lower health literacy and mistrust in authorities. Early in 2021, as a team of vaccine social scientists and clinicians, we developed a program to train and empower community, faith, industry and healthcare leaders to advocate for COVID-19 vaccines as “vaccine champions”. We partnered with the Victorian Department of Health to deliver 91 online Vaccine Champions sessions from March 2021 to June 2022. Over 80 people who received this training were supported by the Department of Health to become formal vaccine champions, independently delivering over 100 locally tailored information sessions. Our survey evaluation of 20 sessions delivered in 2022 found most participants (94%, 118/125) felt more confident to discuss safety and effectiveness of COVID-19 vaccines and find relevant information after attending a session. We also recorded >90% participant satisfaction with training content, format and presentation. Qualitative feedback from two group interviews highlighted the value of vaccine communication role plays and opportunities for discussion. In this brief report, we present an overview of the Vaccine Champions program, evaluation and next steps.
4
Kasaija, Paul D., Marinela Contreras, Halid Kirunda, Ann Nanteza, Fredrick Kabi, Swidiq Mugerwa, and José de la Fuente. "Inspiring Anti-Tick Vaccine Research, Development and Deployment in Tropical Africa for the Control of Cattle Ticks: Review and Insights." Vaccines 11, no. 1 (December 31, 2022): 99. http://dx.doi.org/10.3390/vaccines11010099.
Full textAbstract:
Ticks are worldwide ectoparasites to humans and animals, and are associated with numerous health and economic effects. Threatening over 80% of the global cattle population, tick and tick-borne diseases (TTBDs) particularly constrain livestock production in the East, Central and Southern Africa. This, therefore, makes their control critical to the sustainability of the animal industry in the region. Since ticks are developing resistance against acaricides, anti-tick vaccines (ATVs) have been proposed as an environmentally friendly control alternative. Whereas they have been used in Latin America and Australia to reduce tick populations, pathogenic infections and number of acaricide treatments, commercially registered ATVs have not been adopted in tropical Africa for tick control. This is majorly due to their limited protection against economically important tick species of Africa and lack of research. Recent advances in various omics technologies and reverse vaccinology have enabled the identification of many candidate anti-tick antigens (ATAs), and are likely to usher in the next generation of vaccines, for which Africa should prepare to embrace. Herein, we highlight some scientific principles and approaches that have been used to identify ATAs, outline characteristics of a desirable ATA for vaccine design and propose the need for African governments to investment in ATV research to develop vaccines relevant to local tick species (personalized vaccines). We have also discussed the prospect of incorporating anti-tick vaccines into the integrated TTBDs control strategies in the sub-Saharan Africa, citing the case of Uganda.
5
Colditz, I. G., D. L. Watson, R. Kilgour, D. M. Ferguson, C. Prideaux, J. Ruby, P. D. Kirkland, and K. Sullivan. "Impact of animal health and welfare research within the CRC for Cattle and Beef Quality on Australian beef production." Australian Journal of Experimental Agriculture 46, no. 2 (2006): 233. http://dx.doi.org/10.1071/ea05211.
Full textAbstract:
Research within the health and welfare program of the Cooperative Research Centre for Cattle and Beef Quality has delivered important improvements to the Australian cattle industry. Vaccines to assist with the control of bovine respiratory disease were developed and commercialised from Australian isolates of Mannheimia haemolytica and pestivirus (mucosal disease). Our understanding of the benefits of weaning cattle by confinement and hand feeding in yards (yard weaning) has been consolidated, and yard weaning has been adopted as ‘best practice’ for cattle production in the temperate zones of Australia. The importance of good temperament for improved growth rates and reduced morbidity during feedlot finishing, and for adaptation to stressors such as road transport, has been demonstrated. In response to this knowledge, industry is increasingly measuring flight time for use in breeding programs and feedlot management. The risk to meat quality of stressors such as mixing unfamiliar cattle in the weeks preceding slaughter or acute stress in the last 15 min before slaughter has been described. Adoption of these findings through Quality Assurance schemes will assist in assurance for the community and for export markets of the welfare standards of the Australian cattle and beef industry. This review provides details of the experiments that led to these achievements and to some improved understandings of temperament and behaviour of beef cattle.
6
Moore, Robert J. "Necrotic enteritis in chickens: an important disease caused by Clostridium perfringens." Microbiology Australia 36, no. 3 (2015): 118. http://dx.doi.org/10.1071/ma15041.
Full textAbstract:
Clostridium perfringens, a spore-forming, Gram-positive, anaerobic bacterium, causes a variety of diseases throughout the animal kingdom. Each disease in each animal species tends to be caused by particular strains of C. perfringens and is defined by the tissue tropism and toxin profile of the bacteria. In chickens toxinotype A strains cause necrotic enteritis; a disease characterised by tissue damage to the proximal regions of the small intestine. In extreme cases the disease can be lethal but is more commonly seen as a sub-clinical disease that causes welfare issues and productivity losses within the poultry industry. The disease is currently well controlled in Australia by good management practices and, for some poultry producers, the use of antibiotics in the feed. However, the disease does cause significant issues in other regions including North America and Europe. In Europe there was a spike of necrotic enteritis disease when antibiotics were withdrawn from animal feeds. It is probable that the disease will become more of an issue in the Australian poultry industry as in-feed antibiotic use is reduced. Therefore, other methods of disease control are under investigation, including the development of vaccines.
7
Bindon, B. M. "Genesis of the Cooperative Research Centre for the Cattle and Beef Industry: integration of resources for beef quality research (1993-2000)." Australian Journal of Experimental Agriculture 41, no. 7 (2001): 843. http://dx.doi.org/10.1071/ea00067.
Full textAbstract:
The Cooperative Research Centre for the Cattle and Beef Industry (Meat Quality) was formulated in 1992 by CSIRO, the University of New England (UNE), NSW Agriculture and Queensland Department of Primary Industries (QDPI) to address the emerging beef quality issue facing the Australian beef industry at that time: the demand from domestic and export consumers for beef of consistent eating quality. An integrated program of research involving meat science, molecular and quantitative genetics and growth and nutrition was developed. To meet the expectations of the Commonwealth of Australia, additional projects dealing with animal health and welfare and environmental waste generated by feedlot cattle were included. The program targeted both grain- and grass-finished cattle from temperate and tropical Australian environments. Integration of research on this scale could not have been achieved by any of the participating institutions working alone. This paper describes the financial and physical resources needed to implement the program and the management expertise necessary for its completion. The experience of developing and running the Cooperative Research Centre confirms the complexity and cost of taking large numbers of pedigreed cattle through to carcass and meat quality evaluation. Because of the need to capture the commercial value of the carcass, it was necessary to work within the commercial abattoir system. During the life of the Cooperative Research Centre, abattoir closure and/or their willingness to tolerate the Research Centre’s experimental requirements saw the Cooperative Research Centre operations move to 6 different abattoirs in 2 states, each time losing some precision and considerable revenue. This type of constraint explains why bovine meat science investigations on this scale have not previously been attempted. The Cooperative Research Centre project demonstrates the importance of generous industry participation, particularly in cattle breeding initiatives. Such involvement, together with the leadership provided by an industry-driven Board guarantees early uptake of results by beef industry end-users. The Cooperative Research Centre results now provide the blueprint for genetic improvement of beef quality traits in Australian cattle herds. Heritabilities of beef tenderness, eating quality, marbling, fatness and retail beef yields are now recorded. Genetic correlations between these traits and growth traits are also available. Outstanding sires for beef quality have been identified. Linked genetic markers for some traits have been described and commercialised. Non-genetic effects on beef quality have been quantified. Australian vaccines against bovine respiratory disease have been developed and commercialised, leading to a reduction in antibiotic use and better cattle performance. Sustainable re-use of feedlot waste has been devised.
8
Jeremijenko, Andrew. "Viral mutations, vaccine effectiveness and rapid tests – COVID-19 risk management in the two largest LNG producing countries, Qatar and Australia." APPEA Journal 62, no. 2 (May 13, 2022): S291—S294. http://dx.doi.org/10.1071/aj21059.
Full textAbstract:
The SARS-CoV-2 pandemic created challenges for the oil and gas industry. Qatar experienced three significant waves during the pandemic that disproportionately affected the workers in shared accommodation. In Australia, the public health measures limited the spread of SARS-CoV-2 in the industry until the Omicron wave. Anti-SARS-CoV-2 seropositivity was assessed in five oil and gas subcontractors and five hospital subcontractors in Qatar between 21 June and 9 September 2020. Vaccine effectiveness was assessed in Qatar. Vaccine effectiveness in an LNG tanker crew off Gladstone was calculated. The initial study in Qatar included 4970 craft manual workers (CMWs) who were mostly men (95.0%). Infection positivity (antibody and/or polymerase chain reaction (PCR) positive) ranged from 62.5% (95% CI: 58.3–66.7%) to 83.8% (95% CI: 79.1–87.7%). Only five infections were severe and one was critical – an infection severity rate of 0.2% (95% CI: 0.1–0.4%). Rapid antibody tests (RATs) were effective in diagnosis of the SARS-CoV-2 virus infections. Vaccine effectiveness against severe, critical or fatal infections were above 90% in both the Qatar and Australian studies, but protection against infection waned significantly after 6 months. In Qatar and Australia, the industry implemented effective control measures including the use of RATs, PCR tests, test, trace, isolation, quarantine (TTIQ) and vaccination. In both countries, the LNG industry collaborated with public health experts and other experts and was involved in research to assess and manage the risk of COVID-19. Production of LNG was not affected. Participation in public health research in both countries contributed to important scientific publications and protected the industry. COVID-19 may become endemic.
9
Webster, John, Bethany Bowring, Leah Stroud, Ian Marsh, Narelle Sales, and Daniel Bogema. "Population Structure and Genomic Characteristics of Australian Erysipelothrix rhusiopathiae Reveals Unobserved Diversity in the Australian Pig Industry." Microorganisms 11, no. 2 (January 23, 2023): 297. http://dx.doi.org/10.3390/microorganisms11020297.
Full textAbstract:
Erysipelothrix rhusiopathiae is a bacterial pathogen that is the causative agent of erysipelas in a variety of animals, including swine, emus, turkeys, muskox, caribou, moose, and humans. This study aims to investigate the population structure and genomic features of Australian isolates of E. rhusiopathiae in the Australian pig industry and compare them to the broader scope of isolates worldwide. A total of 178 isolates (154 Australian, seven vaccine isolates, six international isolates, and 11 of unknown origin) in this study were screened against an MLST scheme and publicly available reference isolates, identifying 59 new alleles, with isolates separating into two main single locus variant groups. Investigation with BLASTn revealed the presence of the spaA gene in 171 (96%) of the isolates, with three main groups of SpaA protein sequences observed amongst the isolates. Novel SpaA protein sequences, categorised here as group 3 sequences, consisted of two sequence types forming separate clades to groups 1 and 2, with amino acid variants at positions 195 (D/A), 303 (G/E) and 323(P/L). In addition to the newly identified groups, five new variant positions were identified, 124 (S/N), 307 (Q/R), 323 (P/L), 379 (M/I), and 400 (V/I). Resistance screening identified genes related to lincomycin, streptomycin, erythromycin, and tetracycline resistance. Of the 29 isolates carrying these resistance genes, 82% belonged to SpaA group 2-N101S (n = 22) or 2-N101S-I257L (n = 2). In addition, 79% (n = 23) of these 29 isolates belonged to MLST group ST 5. Our results illustrate that Australia appears to have a unique diversity of E. rhusiopathiae isolates in pig production industries within the wider global context of isolates.
10
Ambepitiya Wickramasinghe, I. N., R. P. de Vries, E. A. W. S. Weerts, S. J. van Beurden, W. Peng, R. McBride, M. Ducatez, et al. "Novel Receptor Specificity of Avian Gammacoronaviruses That Cause Enteritis." Journal of Virology 89, no. 17 (June 10, 2015): 8783–92. http://dx.doi.org/10.1128/jvi.00745-15.
Full textAbstract:
ABSTRACTViruses exploit molecules on the target membrane as receptors for attachment and entry into host cells. Thus, receptor expression patterns can define viral tissue tropism and might to some extent predict the susceptibility of a host to a particular virus. Previously, others and we have shown that respiratory pathogens of the genusGammacoronavirus, including chicken infectious bronchitis virus (IBV), require specific α2,3-linked sialylated glycans for attachment and entry. Here, we studied determinants of binding of enterotropic avian gammacoronaviruses, including turkey coronavirus (TCoV), guineafowl coronavirus (GfCoV), and quail coronavirus (QCoV), which are evolutionarily distant from respiratory avian coronaviruses based on the viral attachment protein spike (S1). We profiled the binding of recombinantly expressed S1 proteins of TCoV, GfCoV, and QCoV to tissues of their respective hosts. Protein histochemistry showed that the tissue binding specificity of S1 proteins of turkey, quail, and guineafowl CoVs was limited to intestinal tissues of each particular host, in accordance with the reported pathogenicity of these virusesin vivo. Glycan array analyses revealed that, in contrast to the S1 protein of IBV, S1 proteins of enteric gammacoronaviruses recognize a unique set of nonsialylated type 2 poly-N-acetyl-lactosamines. Lectin histochemistry as well as tissue binding patterns of TCoV S1 further indicated that these complex N-glycans are prominently expressed on the intestinal tract of various avian species. In conclusion, our data demonstrate not only that enteric gammacoronaviruses recognize a novel glycan receptor but also that enterotropism may be correlated with the high specificity of spike proteins for such glycans expressed in the intestines of the avian host.IMPORTANCEAvian coronaviruses are economically important viruses for the poultry industry. While infectious bronchitis virus (IBV), a respiratory pathogen of chickens, is rather well known, other viruses of the genusGammacoronavirus, including those causing enteric disease, are hardly studied. In turkey, guineafowl, and quail, coronaviruses have been reported to be the major causative agent of enteric diseases. Specifically, turkey coronavirus outbreaks have been reported in North America, Europe, and Australia for several decades. Recently, a gammacoronavirus was isolated from guineafowl with fulminating disease. To date, it is not clear why these avian coronaviruses are enteropathogenic, whereas other closely related avian coronaviruses like IBV cause respiratory disease. A comprehensive understanding of the tropism and pathogenicity of these viruses explained by their receptor specificity and receptor expression on tissues was therefore needed. Here, we identify a novel glycan receptor for enteric avian coronaviruses, which will further support the development of vaccines.
11
Moate, Peter J., Matthew H. Deighton, S. Richard O. Williams, Jennie E. Pryce, Ben J. Hayes, Joe L. Jacobs, Richard J. Eckard, Murray C. Hannah, and William J. Wales. "Reducing the carbon footprint of Australian milk production by mitigation of enteric methane emissions." Animal Production Science 56, no. 7 (2016): 1017. http://dx.doi.org/10.1071/an15222.
Full textAbstract:
This review examines research aimed at reducing enteric methane emissions from the Australian dairy industry. Calorimeter measurements of 220 forage-fed cows indicate an average methane yield of 21.1 g methane (CH4)/kg dry matter intake. Adoption of this empirical methane yield, rather than the equation currently used in the Australian greenhouse gas inventory, would reduce the methane emissions attributed to the Australian dairy industry by ~10%. Research also indicates that dietary lipid supplements and feeding high amounts of wheat substantially reduce methane emissions. It is estimated that, in 1980, the Australian dairy industry produced ~185 000 t of enteric methane and total enteric methane intensity was ~33.6 g CH4/kg milk. In 2010, the estimated production of enteric methane was 182 000 t, but total enteric methane intensity had declined ~40% to 19.9 g CH4/kg milk. This remarkable decline in methane intensity and the resultant improvement in the carbon footprint of Australian milk production was mainly achieved by increased per-cow milk yield, brought about by the on-farm adoption of research findings related to the feeding and breeding of dairy cows. Options currently available to further reduce the carbon footprint of Australian milk production include the feeding of lipid-rich supplements such as cottonseed, brewers grains, cold-pressed canola, hominy meal and grape marc, as well as feeding of higher rates of wheat. Future technologies for further reducing methane emissions include genetic selection of cows for improved feed conversion to milk or low methane intensity, vaccines to reduce ruminal methanogens and chemical inhibitors of methanogenesis.
12
McGowan, Michael, Kieren McCosker, Geoff Fordyce, and Peter Kirkland. "Epidemiology and Management of BVDV in Rangeland Beef Breeding Herds in Northern Australia." Viruses 12, no. 10 (September 23, 2020): 1063. http://dx.doi.org/10.3390/v12101063.
Full textAbstract:
Approximately 60% of Australia’s beef cattle are located in the vast rangelands of northern Australia. Despite the often low stocking densities and extensive management practices of the observed herd, animal prevalence of BVDV infection and typical rates of transmission are similar to those observed in intensively managed herds in southern Australia and elsewhere in the world. A recent large three- to four-year study of factors affecting the reproductive performance of breeding herds in this region found that where there was evidence of widespread and/or recent BVDV infection, the percentage of lactating cows that became pregnant within four months of calving was reduced by 23%, and calf wastage was increased by 9%. BVDV is now considered the second most important endemic disease affecting beef cattle in northern Australia, costing the industry an estimated AUD 50.9 million annually. Although an effective killed vaccine was released in Australia in 2003, the adoption of routine whole herd vaccination by commercial beef farmers has been slow. However, routine testing to identify persistently infected replacement breeding bulls and heifers has been more widely adopted.
13
Venkatas, J., and M. A. Adeleke. "Emerging threat of Eimeria operational taxonomic units (OTUs) on poultry production." Parasitology 146, no. 13 (September 10, 2019): 1615–19. http://dx.doi.org/10.1017/s0031182019001100.
Full textAbstract:
AbstractCoccidiosis is an antagonistic poultry disease which negatively impacts animal welfare and productivity. The disease is caused by an obligate, intracellular protozoon known as Eimeria. Several Eimeria species known to infect chickens have been well documented. However, recent studies have elucidated the emergence of three novel genetic variants or operational taxonomic units (OTUs). The discovery of OTUx, OTUy and OTUz complicates the identification and diagnosis of coccidiosis. OTUs are clusters of unknown or uncultivated organisms that are grouped according to a similarity in DNA sequence to a set of specific gene markers. OTUs have been reported in the Earth's Southern Hemisphere, including Australia, Venezuela, India, Zambia, Uganda, Tanzania, China and Ghana. Elucidating their impact on the poultry industry is fundamental in preventing anticoccidial resistance and to access the potential of OTUs as vaccine candidates to provide cross-protection against similar Eimeria species. The identification of OTUs further decreases the risk of false negative coccidial diagnosis. Therefore, this article reviews the importance and risk imposed by OTUs, coupled with their prevalence and geographical distribution in chickens globally.
14
Strive, T., C. M. Hardy, and G. H. Reubel. "Prospects for immunocontraception in the European red fox (Vulpes vulpes)." Wildlife Research 34, no. 7 (2007): 523. http://dx.doi.org/10.1071/wr07007.
Full textAbstract:
The European red fox is an introduced pest species in Australia for which improved means of control are urgently needed. Research efforts have focussed recently on the development of novel biological control methods to reduce the serious impact this species continues to have on both native fauna and the sheep industry. The ultimate goal has been to generate an antifertility vaccine for use on foxes that relies on a process termed ‘immunocontraception’. A variety of proteins derived from sperm and oocytes, together with different delivery vectors, have been experimentally assessed for their ability to induce immunocontraceptive responses in foxes. Vaccine vectors screened have included Salmonella typhimurium, vaccinia virus and canine herpesvirus but suppression of fertility has yet to be achieved with any combination of antigen and delivery vector. Downregulation of fox mucosal antibodies during oestrus, lack of vector replication and low antibody responses to the target antigens have been the main constraints in successful fertility control. The fox is not well known as an experimental animal and the logistics of dealing with this difficult-to-handle species proved to be a major challenge when compared with other species, such as rabbits and mice. Despite these difficulties, research on fox immunocontraception has generated important insights into the reproductive biology, husbandry, biology and basic immunology of viral vectors in European red foxes. This information represents a valuable knowledge base should antifertility vaccination for foxes be revisited in the future.
15
Kopp, Kayla, Marta Hernandez-Jover, Susan Robertson, Angel Abuelo, and Michael Friend. "A Survey of New South Wales Sheep Producer Practices and Perceptions on Lamb Mortality and Ewe Supplementation." Animals 10, no. 9 (September 5, 2020): 1586. http://dx.doi.org/10.3390/ani10091586.
Full textAbstract:
High lamb mortality rates reduce profitability and reduce the perceived animal welfare standards of the industry. This study aimed to understand producer knowledge of lamb mortality rates and causes of lamb mortality, and to investigate various practices and perceptions of producers that may contribute to lamb deaths. Postal and online surveys gathered data on Australian sheep producer’s knowledge and practices around lambing and management practices. Based on results, approximately 50% of producers estimated less than 10% mortality of lambs between birth and marking, compared to published data estimates of 20–25% mortality. Pre-lambing vaccination of ewes was not undertaken by 10–20% of producers. Ninety-six percent of producers vaccinated lambs; however, 17% of Merino and 23% of crossbred lamb producers only gave a single vaccination instead of the recommended initial vaccine and booster. The lower estimated mortality impacts producer’s perceived benefits of management strategies being undertaken. Research undertaken needs to be more effectively distributed to producers via extension services to ensure producers understand the causes of mortality. Important messages to convey to producers include the limited impact of predation in most cases and the total costs of lamb mortality on-farm.
16
MIROSŁAW, PAWEŁ, and MIROSŁAW POLAK. "New pestiviruses of animals." Medycyna Weterynaryjna 75, no. 01 (2019): 6176–2019. http://dx.doi.org/10.21521/mw.6176.
Full textAbstract:
Viruses of the genus Pestivirus, family Flaviviridae, are believed to be among the main factors causing economic losses in cattle and pig breeding. Their genomes, consisting of single-stranded RNA with positive polarity and a length of approximately 12.3 kb, have one open reading frame that encodes from 11 to 12 proteins. The virion is surrounded by a lipid membrane. According to the official classification, the genus Pestivirus includes four species: bovine viral diarrhea virus-1 (BVDV-1), bovine viral diarrhea virus-2 (BVDV-2), classical swine fever virus (CSFV) and border disease virus (BDV). To date, several genetically related viruses have been identified, but not yet included in the official classification. They include: giraffe pestivirus isolated from an animal with symptoms of mucosal disease and from cell cultures originating from Kenya, Pronghorn virus from an antelope, HoBi-like viruses detected for the first time in fetal bovine serum and Bungowannah virus causing losses in the Australian domestic pig population. It is suspected that new strains detected in Turkish goat and sheep herds and in Tunisian sheep pox vaccines also belong to pestiviruses. Next-generation sequencing has made it possible to identify another atypical pestivirus of pigs, as well as to discover strains infecting other animals beyond the order of Artiodactyla, such as rats or bats. New emerging strains may pose a threat to the livestock industry.
17
Suryaman, G. K., R. D. Soejoedono, A. Setiyono, O. N. Poetri, and E. Handharyani. "Isolation and characterization of avian coronavirus from healthy Eclectus parrots (Eclectus roratus) from Indonesia." November-2019 12, no. 11 (November 2019): 1797–805. http://dx.doi.org/10.14202/vetworld.2019.1797-1805.
Full textAbstract:
Background and Aim: Avian coronavirus has a wide range of hosts, from chickens and turkeys to wild birds. This virus causes an economically and, possibly, environmentally, important loss in the poultry industry. Therefore, research into the avian coronavirus in various species of birds is required. The Eclectus parrot (Eclectus roratus) is an endemic bird to Indonesia and Northern Australia and often kept as pets. At present, there has been limited information about avian coronavirus infection among birds. This study aimed to determine the presence of and to characterize avian coronavirus isolated from Eclectus parrots in Indonesia. Materials and Methods: Cloacal swab samples were taken from 10 healthy Eclectus parrots (E. roratus). Each isolate was propagated into specific pathogen-free embryonated chicken eggs. The presence of avian coronavirus was determined using three sets of primers targeting the 3' untranslated region (3'-UTR) of avian coronavirus (UTR41+/11–), the N gene of the infectious bronchitis virus (IBVN+/–), and the S1 gene of the IBV (XCE2+/XCE2–). The infectious bronchitis vaccine strain H120 was used as a positive control. Resulting positive bands were sequenced for the S1 gene. Results: None of the isolates was positive for the 3'-UTR, four isolates were positive for the N gene of infectious bronchitis, and two isolates were positive for the S1 gene of the IBV. However, only one isolate (parrot/Indonesia/BX9/16) was sequenced for the partial S1 gene with primers XCE2+/XCE2–. The partial nucleotide sequence of this isolate showed 100% homology with the IBV GI-13 lineage, specifically with a field isolate of the 4/91 variant 1 Israel and the 4/91 vaccine on the hypervariable region 3 site of the S1 gene. Conclusion: An IB-like avian coronavirus was isolated from healthy Eclectus parrots. Our results indicate that IBV has a wide range of hosts, which prompt the need to understand the interspecies connection of this virus better.
18
Liu, Fan, Rebecca S. Morrison, Amy K. Lealiifano, Chris J. Brewster, David J. Henman, and Robert J. Smits. "Shortening the immunocastration-to-slaughter interval from 3 to 2 weeks reduced carcass backfat and weight, increased sexual behaviour and carcass skin blemishes in group-housed male pigs sold at fixed age." Animal Production Science 61, no. 7 (2021): 673. http://dx.doi.org/10.1071/an20428.
Full textAbstract:
Context Pig producers require strategies to temporarily slow growth rate, particularly when markets impose penalties on over-weight and fat carcasses. Immunocastrated pigs usually have higher feed intakes (e.g. during the 3–5-week immunocastration-to-slaughter interval, which is commonly used in Australian pig industry), resulting in higher carcass weight and backfat thickness. Shortening the immunocastration-to-slaughter interval by delaying the second vaccination by a week may be a fine-tuned strategy to reduce carcass backfat and weight of male pigs. However, postponing the age receiving immunocastration as a method to achieve a shorter immunocastration-to-slaughter interval may increase aggressive and sexual behaviours of pigs. Aims The experiment aimed to quantify the effects of shortening the interval between the second dose of immunocastration and slaughter from 3 weeks to 2 weeks on growth performance, carcass traits, aggressive and sexual behaviours, and carcass skin blemishes in group-housed male finisher pigs slaughtered at a fixed age. Methods Pigs (n = 58 pens; 45 pigs per pen) were selected into the experiment at 16 weeks of age. Half of the pens received the second anti-GnRH vaccine (V2) as a means of immunocastration at 19 weeks (a common immunocastration age used in Australian pig industry; control group), and the remaining half of the pens received V2 at 20 weeks of age. All the pigs were slaughtered at 22 weeks of age. Growth performance was recorded between 16 and 22 weeks of age. Behavioural observation was conducted at 20 and 21 weeks of age. Carcass weight, backfat thickness and severity of skin blemishes on carcasses were recorded in the abattoir. Key results Results showed that shortening the immunocastration-to-slaughter interval from 3 to 2 weeks reduced average daily feed intake by 9%, growth rate by 8%, carcass weight by 3%, and backfat thickness by 7% (all P < 0.05), but the percentage of pigs that displayed sexual behaviour and carcasses with >25 lesions both increased (both P < 0.05). Conclusions Shortening the immunocastration-to-slaughter interval from 3 to 2 weeks by delaying V2 is an effective strategy to reduce feed intake, growth rate, carcass weight and backfat in group-housed male pigs, but at a risk of increasing carcass skin blemishes. Implications The increased sexual behaviour and carcass skin blemishes will need to be managed when using a shortened immunocastration-to-slaughter interval to temporarily reduce carcass weight and backfat.
19
Links, Ian J., Laurence J. Denholm, Marilyn Evers, Lloyd J. Kingham, and Robert J. Greenstein. "Is vaccination a viable method to control Johne’s disease caused by Mycobacterium avium subsp. paratuberculosis? Data from 12 million ovine vaccinations and 7.6 million carcass examinations in New South Wales, Australia from 1999–2009." PLOS ONE 16, no. 6 (June 14, 2021): e0246411. http://dx.doi.org/10.1371/journal.pone.0246411.
Full textAbstract:
Background Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne’s disease (or paratuberculosis), a chronic wasting disease of ruminants and other animals resulting from granulomatous enteritis. There are increasing concerns that MAP is zoonotic. The prevalence of Johne’s disease is increasing worldwide. In an attempt to control an epidemic of ovine Johne’s disease (OJD) in New South Wales (NSW), a government/industry sponsored voluntary vaccination/on-farm management program commenced in 2000. We report herein an observational study of changes in disease prevalence as vaccination progressed, based on abattoir surveillance data for OJD from 1999 to 2009. We also discuss the epidemiological, policy, regulatory, research, economic and sociological elements that contributed to the development of a mature control program, whose aim was to halt the epidemic spread of OJD in a naïve sheep population. Methods NSW was divided into areas of “High” (HPA), “Medium” (MPA) and “Low” (LPA) OJD prevalence. A killed whole cell vaccine (Gudair®) was administered to sheep from 2000 to 2009. Trained examiners evaluated the viscera of adult sheep carcasses at slaughter for gross evidence of OJD. MAP infection was confirmed by histopathology. Principal findings From 2000–2009, 12 million vaccine doses were administered in NSW (91%; 10.9 million in the HPA). Many of the vaccinated flocks were suffering > 5% annual mortality in adult sheep, with some individual flocks with 10–15% losses attributable to OJD. A total of 7.6 million carcasses were examined (38%; 2.9 million from the HPA). Overall, 16% of slaughter consignments (sheep consigned to the abattoir from a single vendor) were positive for OJD, of which 94% were from the HPA. In the HPA, the percentage of animals with lesions attributable to OJD at slaughter fell progressively from 2.4% (10,406/432,860) at commencement of vaccination in 2000 to 0.8% (1,573/189,564) by 2009. Herd immunity from vaccination in the HPA was estimated at 70% by 2009, the target commonly espoused for an effective control program based on vaccination. This coincided with a progressive decrease in reports of clinical disease and mortalities in vaccinated flocks. Significance We show a decrease in the prevalence of lesions attributable to OJD in NSW concomitant with initiation of voluntary vaccination, on-farm management plans, abattoir monitoring and feedback of animal prevalence data to sheep producers. We conclude that a target of ≤ 1% regional prevalence of OJD affected sheep at slaughter is achievable using these interventions.
20
Kumar, Roshan, Karen Register, Jane Christopher-Hennings, Paolo Moroni, Gloria Gioia, Nuria Garcia-Fernandez, Julia Nelson, et al. "Population Genomic Analysis of Mycoplasma bovis Elucidates Geographical Variations and Genes associated with Host-Types." Microorganisms 8, no. 10 (October 10, 2020): 1561. http://dx.doi.org/10.3390/microorganisms8101561.
Full textAbstract:
Among more than twenty species belonging to the class Mollecutes, Mycoplasma bovis is the most common cause of bovine mycoplasmosis in North America and Europe. Bovine mycoplasmosis causes significant economic loss in the cattle industry. The number of M. bovis positive herds recently has increased in North America and Europe. Since antibiotic treatment is ineffective and no efficient vaccine is available, M. bovis induced mycoplasmosis is primarily controlled by herd management measures such as the restriction of moving infected animals out of the herds and culling of infected or shedders of M. bovis. To better understand the population structure and genomic factors that may contribute to its transmission, we sequenced 147 M. bovis strains isolated from four different countries viz. USA (n = 121), Canada (n = 22), Israel (n = 3) and Lithuania (n = 1). All except two of the isolates (KRB1 and KRB8) were isolated from two host types i.e., bovine (n = 75) and bison (n = 70). We performed a large-scale comparative analysis of M. bovis genomes by integrating 103 publicly available genomes and our dataset (250 total genomes). Whole genome single nucleotide polymorphism (SNP) based phylogeny using M.agalactiae as an outgroup revealed that M. bovis population structure is composed of five different clades. USA isolates showed a high degree of genomic divergence in comparison to the Australian isolates. Based on host of origin, all the isolates in clade IV was of bovine origin, whereas majority of the isolates in clades III and V was of bison origin. Our comparative genome analysis also revealed that M. bovis has an open pangenome with a large breadth of unexplored diversity of genes. The function based analysis of autogenous vaccine candidates (n = 10) included in this study revealed that their functional diversity does not span the genomic diversity observed in all five clades identified in this study. Our study also found that M. bovis genome harbors a large number of IS elements and their number increases significantly (p = 7.8 × 10−6) as the genome size increases. Collectively, the genome data and the whole genome-based population analysis in this study may help to develop better understanding of M. bovis induced mycoplasmosis in cattle.
21
"Bioboard." Asia-Pacific Biotech News 13, no. 08 (August 2009): 3–12. http://dx.doi.org/10.1142/s0219030309000494.
Full textAbstract:
AUSTRALIA – AIBN and US Researchers Join Forces. AUSTRALIA – Harmless Gene Mutation Could Trigger Bowel Cancer. AUSTRALIA – Australian Researchers Identify Melanoma Genes. AUSTRALIA – UQ Generates First Australian Swine Flu Vaccine. CHINA – Molecular Biologists Report New Immune Tolerance Mechanism. CHINA – H1N1 Patients to Pay for their Own Treatment. CHINA – China Begins Tests for First H1N1 Flu Vaccines. INDIA – Stem Cells Could Regenerate Insulin-Secreting Tissues. INDIA – Ayurveda Drug for Cancer. INDIA – Global Medical Travel Industry To Grow 15-20% Annually. JAPAN – Japanese Scientists Unveil Ultra-thin Surgical Patch. SINGAPORE – US$10.4m Awarded to 8 Clean Energy Research Teams. SINGAPORE – Strong Biomedical Sector Pulls Singapore Out of Recession. SINGAPORE – Nanotechnology Combats Fatal Brain Infections. SINGAPORE – Singapore Doctor Pioneers Concept of Biological Transplant for Bone Cancer. VIETNAM – Cancer Tops List of Diseases Contracted in Vietnam. OTHER REGIONS — NORTH AMERICA – U.S. Researchers Map Melon Genome. OTHER REGIONS — EUROPE – Big Firms said to be Delaying Cheaper Drugs. OTHER REGIONS — EUROPE – Humans can Give Swine Flu to Pigs.
22
"Industry Watch." Asia-Pacific Biotech News 14, no. 04 (April 2010): 23–35. http://dx.doi.org/10.1142/s0219030310000200.
Full textAbstract:
Integrated DNA Technologies and Glycon Partner in Australia. Phosphagenics to Develop Transdermal Insulin for Pets. NanoMaterials Technology Signs Exclusive Licensing Agreement for Hyperlipidemia-controlling Drug with Beijing Winsunny Pharmaceutical. MicuRx Pharmaceuticals,Cumencor Pharmaceuticals Partner with Pfizer to Discover and Develop Antibiotics for Drug-Resistant TBChina. Qiagen Ties up with Chinese University. Syngene to Collaborate with Endo Pharmaceuticals to Develop Anti-cancer Novel Therapeutic Molecules. Ranbaxy Collaborates With Pfenex on Development of Biosimilar Therapeutic Protein. Metabolex Initiates Research Collaboration with Takeda. AMAG, Takeda Agree to Collaborate on Feraheme Injection. Medicago Signs MOU with NITT Partners for Commercial Development of Influenza Vaccines in Japan. ICON to Open New Office in Philippines. HealthLinx Soon to Launch OvPlex in Singapore. Invida Strengthens Asia-Pacific Presence Analysis.
23
"9.H. Workshop: Mandatory vaccination policies: development, effectiveness, politics and consequences." European Journal of Public Health 30, Supplement_5 (September 1, 2020). http://dx.doi.org/10.1093/eurpub/ckaa165.471.
Full textAbstract:
Abstract Australia, Italy, France, California, Germany and several US states have new mandatory vaccination regimes. Contemporary vaccine mandates include more vaccines, more consequences for non-vaccinators, more enforcement sites, and less exemptions. Policymakers and scholars alike face pressing questions regarding the development, effectiveness, politics and unintended consequences of new mandates. Dr Attwell, co-convenor, currently leads this nascent field in conceptual, theoretical and empirical work through a major Australian-government funded research project. She presents an overview of her work and methodologies in the workshop's Introduction. By convening a session with top international scholars, we disseminate key research findings in a forum ideally suited for interaction between presenters and attendees, establishing a global research network to consider the questions outlined above. We forge and facilitate new collaborations with attending scholars and key actors in global vaccination policy to fill research gaps. We also give policymakers a clear sense of the global field, including what requires consideration when contemplating or designing vaccine mandates. Initial inquiries indicate high levels of interest from individuals and organisations planning to attend the World Congress (or would attend to participate in our workshop). These include UNICEF and scholars from Europe, Australasia and North America, in addition to our multi-continental presenters. We will heavily promote the workshop within our extensive professional networks, as well as within WHO, the Vaccination Acceptance Research Network, the Fondation Merieux, and industry. We anticipate great interest from these organisations, most of which are familiar with our work. The five presentations include empirical work at various stages of the policy cycle, and global overviews of mandatory policies. They will be presented back-to-back, followed by an extended audience Q&A and discussion moderated by co-convenor Dr Paul. Attwell and Rizzi consider policy development in Italy, exploring conflictual aspects of policy transfer, to foster understanding of the dynamics in multilevel states. Continuing the development focus, Deml considers the politics of mandates-crafting and the ambiguity emerging from imprecise language in Switzerland. Danchin picks up at the evaluative end of the policy cycle, considering whether Australia's mandatory policies have changed parents' behaviour. These three focused presentations are augmented by macro-level analyses. MacDonald analyses data from a WHO study, teasing out target groups, consequences and exemptions, and demonstrating patterns of global coverage. Vanderslott reviews 149 countries, drawing out the unintended consequence of developing countries using vaccine mandates when supply and access problems underpin sub-optimal coverage. The mix of macro and micro levels of analysis will allow the workshop to illuminate new areas for study. Key messages The mandatory vaccination workshop coheres an international field of scholars, disseminating knowledge and identify synergies and research gaps in an emerging area of public health governance. Attendees gain a ‘state of the art’ picture of mandatory vaccination policies globally, including significant issues to consider and impacts of these policies, which can guide policy development.
24
"Industry Watch." Asia-Pacific Biotech News 10, no. 12 (June 30, 2006): 661–80. http://dx.doi.org/10.1142/s0219030306000929.
Full textAbstract:
An Australian Company—Solagran Limited. World's First Transdermal Insulin from Australia. Circadian Technologies Ltd Forms New Company, Vegenics. Yale Ovarian Cancer Detection Technology Licensed in China by SurExam. Simcere Pharmaceutical Group Sets Foot in Anticancer Field. Bio-Bridge Science Builds Vaccine Facility in China. Novavax Inc and Bharat Biotech International Partner on the Development of Pandemic Influenza Vaccine. Genesis Receives $5.5M Payment. OraQuick® HIV Test Receives Approvals from Singapore Ministry of Health. Singapore-based SciGen Collaborates with Ferring on Recombinant Human Insulin. Singular ID's Patent Portfolio Strengthens and Grows. Bridge Announces $22 Million Capital Raise.
25
"BioBoard." Asia-Pacific Biotech News 11, no. 05 (March 15, 2007): 259–67. http://dx.doi.org/10.1142/s0219030307000274.
Full textAbstract:
Australia — Australian Scientists Discover a Treatment for Malaria. Australia — Australian of the Year Wins Science Medal. Australia — Industry Researchers Receives Prestigious Awards. Australia — Australia Supports Biotech Start-ups. Australia — Phylogica Receives Funding for Brain Research. China — Enshi Pharma Wins Top Honors. China — Nutra Pharma to Start HIV Drug Production in China. China — CAS, INSERM and Wuhan University to Set Up a Hepatopathy Institute. China — Novartis to Launch Hep B Drug in China. China — China's Top 10 Advances in Basic Research in 2006. China — Local Researchers Rake in 42 National Science Awards. China — China Invited to Join Global Fight Against Disease. China — GlaxoSmithKline to Build Research Center in China. China — China and France to Jointly Develop Traditional Chinese Medicine. India — India Shows a Decline in Number of AIDS Sufferers. India — India and Norway Collaborate on Vaccination Research. India — India Launches Polio Vaccine Drive. India — Agilent Earmarks US$35 Million for India. Indonesia — Vaccine May Treat Many Bird Flu Strains. Malaysia — Malaysian Scientists Develop Herbal Drug for Dengue. New Zealand — New Trans-Tasman Bioscience Pact. Singapore — Scientists Discover Risk Gene in Breast Cancer Patients. Singapore — Ciba to Build Antioxidant Plant in Singapore. South Korea — South Korea Culls 35,000 Ducks in Latest Bird Flu Outbreak. Taiwan — Taiwan Biotech Output Valued at Over US$5.36 Billion. Taiwan — Scientists Plan China, Hong Kong, Taiwan Stem Cell Trial. Taiwan — Taiwan Government Revamps Pharma Regulations. Vietnam — Bird Flu Resurfaces in Southern Vietnam. Others — Asia to Fight Tuberculosis and HIV Infections.
26
"General News." Asia-Pacific Biotech News 07, no. 15 (July 21, 2003): 925–36. http://dx.doi.org/10.1142/s0219030303001708.
Full textAbstract:
Competing Australian States to Co-Promote Aussie Biotech. New GM Wheat to Bypass Australia. Jiangsu Pharmaceutical Industry Thriving. Shenzhen Opens Drug Distribution Market to Foreign Investment. Vadodara to Establish Biotech Park. Monkey Pox Virus Imported to Japan. Increase in Non-Alcoholic Steatohepatitis Sufferers in Japan. Korea Free of SARS Suspects. Increasing Food Poisoning Cases. WHO Head Makes Smoking and AIDS Top Agenda. Upcoming Vaccine Facility in Malaysia. Bioinformatics Applied for Analyzing Brain Disorders. Completion of Trout Genetic Database by Year End.
27
Jeremijenko, Andrew. "Concurrent 19. Presentation for: Viral mutations, vaccine effectiveness and rapid tests – COVID-19 risk management in the two largest LNG producing countries, Qatar and Australia." APPEA Journal 62, no. 4 (June 3, 2022). http://dx.doi.org/10.1071/aj21365.
Full textAbstract:
Presented on Wednesday 18 May: Session 19 The SARS-CoV-2 pandemic created challenges for the oil and gas industry. Qatar experienced three significant waves during the pandemic that disproportionately affected the workers in shared accommodation. In Australia, the public health measures limited the spread of SARS-CoV-2 in the industry until the Omicron wave. Anti-SARS-CoV-2 seropositivity was assessed in five oil and gas subcontractors and five hospital subcontractors in Qatar between 21 June and 9 September 2020. Vaccine effectiveness was assessed in Qatar. Vaccine effectiveness in an LNG tanker crew off Gladstone was calculated. The initial study in Qatar included 4970 craft manual workers (CMWs) who were mostly men (95.0%). Infection positivity (antibody and/or polymerase chain reaction (PCR) positive) ranged from 62.5% (95% CI: 58.3–66.7%) to 83.8% (95% CI: 79.1–87.7%). Only five infections were severe and one was critical – an infection severity rate of 0.2% (95% CI: 0.1–0.4%). Rapid antibody tests (RATs) were effective in diagnosis of the SARS-CoV-2 virus infections. Vaccine effectiveness against severe, critical or fatal infections were above 90% in both the Qatar and Australian studies, but protection against infection waned significantly after 6 months. In Qatar and Australia, the industry implemented effective control measures including the use of RATs, PCR tests, test, trace, isolation, quarantine (TTIQ) and vaccination. In both countries, the LNG industry collaborated with public health experts and other experts and was involved in research to assess and manage the risk of COVID-19. Production of LNG was not affected. Participation in public health research in both countries contributed to important scientific publications and protected the industry. COVID-19 may become endemic. To access the presentation click the link on the right. To read the full paper click here
28
"BIOBOARD." Asia-Pacific Biotech News 15, no. 11 (November 2011): 5–18. http://dx.doi.org/10.1142/s0219030311000656.
Full textAbstract:
AUSTRALIA – IVF Treatment Linked to Tumours. AUSTRALIA – GAT-1 Drives Withdrawal Symptoms. AUSTRALIA – Winners of Student Excellence Awards Showcase Australia's Promising Future in Bio-Sciences. AUSTRALIA – Asthma Treatment Hope After Genetic Discovery. CHINA – Scientists Make Human Blood Protein from Rice. CHINA – India and China Enter Lucrative Biotech Drugs Foray. CHINA – Antibiotics Heavily Overused in China. CHINA – Supplements in China Found to Contain Vet Drugs. INDIA – Health Benefits of Indian Herbs Need Global Focus. KOREA – Stem Cell Breakthrough May Lead to Cure for Parkinson's and Diabetes. KOREA – Multidrug-Resistant Tuberculosis Poses Public Health Risk in N. Korea. KOREA – Drug firm GSK fined US$2.6m for Collusion. SINGAPORE – Platforms for Singapore, Europe Scientists to Collaborate. SINGAPORE – Singapore Experts and Japanese Chemical Leaders Share Green Innovations for Industry. OTHER REGIONS — NCKU Professor Receives Korea's Research Award. OTHER REGIONS — Rejuvenated Stemcells Coaxed from Centenarian. OTHER REGIONS — 'Promising' Step for World's First Malaria Vaccine.
29
"Industry Watch." Asia-Pacific Biotech News 09, no. 19 (October 15, 2005): 998–1007. http://dx.doi.org/10.1142/s0219030305000352.
Full textAbstract:
Leading US Neuroscientist Appointed Chief Scientific Officer of Living Cell Technologies. Trillium Therapeutics Acquires Australia-based Arthron Ltd. Star Pharmaceutical Seeks Singapore Stock Market Listing. Astellas and MerLion Collaborate to Develop Natural Products Drug Candidate. Sumitomo Pharmaceuticals Signs Agreement with Merck & Co. Biosensors Bags US Patent for Heart Stent Technology. MerLion Pharma and Cancer Research Technology Announce Drug Discovery Collaboration. OctoPlus and SingVax Collaborate to Develop Single-shot Japanese Encephalitis Vaccine. Rockeby Moves into African Marketing.
30
"Industry Watch." Asia-Pacific Biotech News 14, no. 01 (January 2010): 23–39. http://dx.doi.org/10.1142/s0219030310000042.
Full textAbstract:
Australian Company Develops Potential UV Vaccine. Phylogica Enters Agreement with Roche to Evaluate Phylomer Technology. CSL Behring Awards $87,000 to Patient Organizations in USA. Pfizer, Crown Bioscience Tie up for Asian Cancers R&D. Sinovac Files Clinical Trial Application with SFDA for Vaccine against Hand, Foot, and Mouth Disease. Takeda and Pfizer to Co-Promote Takeda's Actos® (pioglitazone HCl) for the Treatment of Type 2 Diabetes in China. Alvogen Launches Asia Operations. Praj to Collaborate with Novozymes on Advanced Biofuels. Biocon and HCG Group of Hospitals Join Hands to Fight Against Cervical Cancer. Shantha Introduces India's First Oral Cholera Vaccine. Pfizer, TCGLS to Develop Preclinical Candidate Molecules. Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business. Dicerna Pharma, Kyowa Hakko to Collaborate on RNAi. Ambit Biosciences and Astellas Enter Strategic Partnership. Inno Biologics, CEVEC for Using Sign Agreement Human CAP Technology.
31
"Bioboard." Asia-Pacific Biotech News 13, no. 07 (July 2009): 6–14. http://dx.doi.org/10.1142/s0219030309000433.
Full textAbstract:
AUSTRALIA – US$6.5 Bn for Australia Science and Innovation. AUSTRALIA – Genes Linked to Vitamin D Involved in Susceptibility to Multiple Sclerosis. AUSTRALIA – Scientists Find Weak Link in Malaria Portal. CHINA – China Makes First Pig Stem Cells. CHINA – Genetic Tests to Unravel Prodigies. INDIA – India Can Become a Global Pharma Innovation Hub. INDIA – Anti-diarrhea Vaccine in Development. JAPAN – Inevitable Public Debate over GM Primates. NEW ZEALAND – NZ Biotech Industry Continues to Thrive. SINGAPORE – 'Simulation Model' for Disease Spread. SINGAPORE – Singapore's Challenge: Sustain Environment Long-Term. SINGAPORE – Water Industry Players Partnering Education Sector. SINGAPORE – World-Wide Debut For 16 Inventions. TAIWAN – New Treatment for Uterine Fibroids. TAIWAN – Taiwan to Develop Methods to Test Melamine Tableware. TAIWAN – New Research Expected to Help Develop Universal Flu Vaccine. VIETNAM – Herbal Capsules to Treat Womb Ulcers. OTHER REGIONS — US – Baxter Could Have Pandemic Flu Vaccine in July. OTHER REGIONS — US – Will US Dominate Biotech?
32
"Industry Watch." Asia-Pacific Biotech News 14, no. 11 (November 2010): 29–43. http://dx.doi.org/10.1142/s0219030310000534.
Full textAbstract:
Phylogica Commences Antimicrobial Peptide Discovery under Agreement with MedImmune. Leadtec Systems Australia to Acquire Mimotopes. Sirnaomics Seals Deal for Development of RNAi Therapeutics in China. Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound. Pfizer, Biocon in $350 Million Insulin Pact. Bharat Biotech Announces Launch of 'HNVAC™' India's First Cell-Culture H1N1 Swine Flu Vaccine. Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis). Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration. Philips and Atom Medical Corporation Announce Strategic Alliance to Provide a Complete Neonatal and Perinatal Offering. CiRA and France-based Cellectis Enter Collaboration. Immunovaccine Signs Research Agreement with OncoTherapy Science to Advance Potential Cancer Vaccine. Glycos Biotechnologies Enters Definitive Agreement with Malaysian Bio-XCell. Biocon Plans to Invest $161m in Malaysia to Set Up R&D Unit.
33
"Industry Watch." Asia-Pacific Biotech News 07, no. 26 (December 22, 2003): 1653–66. http://dx.doi.org/10.1142/s0219030303002684.
Full textAbstract:
Strategic Commercial Partnership for Australian Biotech Innovation. AGT Partners IPD in Anti-Obesity Therapies Development. Genesis Biomedical Acquires ENSI~MED. Sulfa Drug Output Increases Despite Declining Demand. China's Pharmaceutical Retail Market in First Half 2003. Shanghai Company Collaborates with Inner Mongolia Pharma Group. Venkateshwara Group Creates New Vaccine Manufacturing Division. Pfizer India Prioritized as Prime R&D Hub. Pharmac Caught in Losec Dispute. Cardinal Health Establishes Singapore Operation.
34
"Industry Watch." Asia-Pacific Biotech News 08, no. 14 (July 30, 2004): 764–78. http://dx.doi.org/10.1142/s0219030304001156.
Full textAbstract:
AustCancer Explores New Market. Australian Stocks Upsurge 24%. EvoGenix Joins Viventia Biotech to create Cancer Therapeutic Antibodies. Nitazoxanide Launched in India. Philippine Government Pushes Biotech. SII Participates in International Meningitis Vaccine Project. Cipla's Pre-qualified AIDS Drugs Lack Bioequivalence Proof. Oral SOU-001 Phase I Clinical Trials Commenced in UK. Chugai Expands Indications for Rocephin. Mitsubishi Pharma Markets Oral HCV Protease Inhibitor in Asia. Pacific Edge Forecasts Financial Boom from Japanese Funds.
35
"Industry Watch." Asia-Pacific Biotech News 11, no. 09 (May 15, 2007): 570–91. http://dx.doi.org/10.1142/s0219030307000626.
Full textAbstract:
Apollo Life Sciences Develops Needle Free Topical Vaccine. Avexa Collaborates with TargetDrug for CCR5 Inhibitor HIV Program. BioMaxx Systems to Build Biodiesel Demonstration Plant in Asia. GSK Plans to Launch Cervarix Vaccine Approved by Australia's Therapeutic Administration. LabTech Systems Signs License Agreement with BioMérieux for Innovative Robotic Microbiological Instrumentation. Living Cell Technologies to Conduct Trials of Pig Islet Cell Transplant in Diabetes Patients. Peptech Plans to Merge with Evogenix. Phylogica Collaborates with Opsona Therapeutics for Drug Discovery. China Sky One Medical Receives Grant from Heilongjiang Government. SinoBiomed's Malaria Vaccine Granted US Patent. Biocon to Enter Phase II Clinical Trials for Oral Insulin. Indian Drug Makers, Ranbaxy and Dr Reddy, Build Therapeutic Bridges in Japan. Medtronic Commences Large-Scale Clinical Trial of CRT-D in Japan. Japan's Bioventures Today — Sun Care Fuels Corporation. MerLion Pharmaceuticals to Conduct Trials for Two Anti-infection Drugs.
36
"Industry Watch." Asia-Pacific Biotech News 07, no. 18 (September 2003): 1103–22. http://dx.doi.org/10.1142/s0219030303001939.
Full textAbstract:
Australian Cancer Technology Acquires US Cancer Care Business. Premier to Accelerate Technology Commercialization Following Trial Success. Starpharma’s Anti-STDs Lead — VivaGel™ Enters Human Clinical Trial. Epitan’s Melanotan® Commences Human Implant Trial. Sinopharm Group Pharmaceutical Co. Established. Swedish Company Perbio Science Sets up Headquarters in Hong Kong. Zydus-Cadila Acquires Alpharma’s French Business. Virionyx Collaborates with US Organizations to Develop SARS Treatment. AgResearch To Develop Potential GMO Vaccine for Tuberculosis. NUS Enterprise Reaps from Horseshoe Crab Research — PryoGene.
37
"BioBoard." Asia-Pacific Biotech News 11, no. 14 (July 30, 2007): 952–57. http://dx.doi.org/10.1142/s0219030307000985.
Full textAbstract:
AUSTRALIA — Australia Commits Extra Fund to Combat AIDS in Asia Pacific. AUSTRALIA — Australia Joins European Molecular Biology Laboratory. AUSTRALIA — Australian Scientists Discovers New Drugs to Treat Childhood Cancer. CHINA — China Tries to Reduce Corruption in Medical Equipment Industry. CHINA — Chinese Police Arrest Fake Drug Ring. CHINA — China Donates US$30 000 to Cambodian Red Cross for Dengue Control. CHINA — Sino-Dutch Center for Plant Molecular Breeding Established in Shanghai. CHINA — Project of S&T for Grain Harvest Launched. CHINA — UNAIDS Chief Heaps Praise on China's Anti-AIDS Efforts. CHINA — China and ASEAN Work as a Team to Fight Against Avian Flu. HONG KONG — Guangdong Province, Macau and Hong Kong Health Authorities Cooperate in Infectious Diseases Control. INDIA — Indian Health Ministry to Finalize Draft on HIV/AIDS Bill. INDONESIA — Indonesia to Step Up Fight Against HIV/AIDS. JAPAN — Japan Scientists Develops Artifical Womb. NEW ZEALAND — Government Urged to Reject Dangerous GM Corn. SINGAPORE — Singapore and France Launch Workshop on Managing Bird Flu Epidemic. SINGAPORE — National Registry of Diseases Act to Help Medical Data Collection for Research. SINGAPORE — New Cervical Cancer Vaccine Available in Singapore Shortly. SOUTH KOREA — Korean Scientists Advance Genome Research with Bioinformatics. TAIWAN — Taiwan to Develop US$900 Million National Biotech Park. OTHERS — Asia Braces for New Dengue Outbreak.
38
"Industry Watch." Asia-Pacific Biotech News 10, no. 22 (November 30, 2006): 1279–95. http://dx.doi.org/10.1142/s0219030306001893.
Full textAbstract:
Australian Listed biotech firms to Benefit from New Alliance. CyGenics Signs Collaboration Agreement with the Blood Center of Zhejiang Province. Shanghai Genomics. CMIC and Accium Collaborate to Provide Exploratory-IND and Low-Radiation PK/ADME Service. Stelic Discovers New Treatment Method for Acute Liver Failure. Japan Bioventures Today — Regimmune Corporation. Inventory Response by Baxter on its Preliminary Findings for Bird Flu Vaccine. Davos Life Science Opens World's Largest R&D Center on Tocotrienols in Singapore. Invitrogen Opens First of its Kind Supply Center in Singapore.
39
"Industry Watch." Asia-Pacific Biotech News 11, no. 01 (January 15, 2007): 24–39. http://dx.doi.org/10.1142/s0219030307000031.
Full textAbstract:
HD Medical and CSIRO Collaborate on Cardiac Diagnostics. Medical Therapies Collaborates with NexMed. Progen's Inventory Results on Phase 2 Liver Cancer Trial. Renhuang Pharmaceuticals Announces Government Grant. Mindray Medical to Establish New R&D and Manufacturing Base in Nanjing. Sterlin Gelatin to Expand in India and China. Favorable Decision Granted to Ranbaxy Laboratories on Pfizer's Australian Atorvastatin Patent. Honeywell Automation India Ltd Plans to Expand into Emerging Indian Pharma Sector. Bharat Biotech Launches Anti Rabies Vaccine — Rabirix. Caliper Life Sciences Announces Expanded Sales on LabChip and Ivis. Japan's Bioventures Today — ImmunoFrontier, Inc.
40
"INSIDE INDUSTRY." Asia-Pacific Biotech News 21, no. 12 (December 2017): 34–44. http://dx.doi.org/10.1142/s0219030317000866.
Full textAbstract:
Asia-Pacific, the rising region for cancer vaccine clinical trials. Non-small cell lung cancer has largest number of clinical trials in Australia. Global dermatology pipeline to see shift towards increased usage of biologics. FDA approves first 0.1 mg auto-injector for life-threatening allergic reactions in infants and small children. FDA approves first two-drug regimen for certain patients with HIV. New early-breast cancer drug to be made available in Australia, New Zealand and South-East Asia. Multi-omic data analytics collaboration between the University of Oxford and Holmusk. NRGene’s genomic analysis project with Monsanto advances. Samsung BioLogics receives first FDA approval at world’s largest plant. TLC welcomes Mayor of Leiden and delegation to Taipei headquarter. Warren Wang appointed senior vice president and president of Asia Pacific of Boston Scientific. MiRXES reveals globalisation plans for 2018 and 2019. QuintilesIMS is now IQVIA. Quotient Sciences launches as the new global identity for Quotient Clinical. ESMO Asia 2017 Congress. More care is needed for cancer supportive care. ALEX study shows alectinib 600 mg more effective than crizotinib in Asian lung cancer patients. Study analyses mutations in cerebrospinal fluid in lung cancer with brain metastases. Study finds all Myanmar mouth cancer patients chew betel quid.
41
Zhao, Weijie. "A forum on synthetic biology: meet the great challenges with new technology." National Science Review, October 17, 2020. http://dx.doi.org/10.1093/nsr/nwaa252.
Full textAbstract:
Abstract Synthetic biology aims to redesign and reconstruct living systems for understanding life or for useful real-world applications. In the past two decades, scientists have been able to use engineered living systems to produce many kinds of products from bioplastics to drugs, to construct a minimal bacterium with a fully synthetic genome and to store huge amount of information within a cell. And in 2020, when the COVID-19 pandemic swept across the world, the synthetic biology community became one of the major forces to develop effective diagnostic approaches as well as the drugs and vaccines, to rapidly cope with this great challenge with the state-of-the-art technologies in their hands. In this panel discussion held on 3rd August 2020, eleven pioneering synthetic biologists from six countries across four continents gathered to discuss the development trend, challenges and biosafety issues concerning synthetic biology. George Church Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT, USA Paul Freemont Professor of Structural Biology in the Department of Infectious Disease at Imperial College and a member of the Science Advisory Board of Tierra Biosciences, UK Akihiko Kondo Professor in School of Science, Technology and Innovation, and Department of Chemical Science and Engineering at Kobe University, Japan Christina Smolke Professor of Bioengineering and of Chemical Engineering at Stanford University and CEO of Antheia Inc., USA Xian-En Zhang Professor at the Institute of Biophysics, Chinese Academy of Sciences, China Chenli Liu (Chair) Professor and Director of Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, China Jim Collins Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, USA Jay Keasling Professor of Chemical Engineering and Bioengineering at the University of California, Berkeley, USA Sang Yup Lee Dean of KAIST Institutes and Distinguished Professor in the Department of Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology (KAIST), Korea Claudia Vickers Director of the Future Science Platform in Synthetic Biology at Commonwealth Science and Industry Research Organization (CSIRO), Australia Guoping Zhao Professor at the Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China
42
"BioBoard." Asia-Pacific Biotech News 11, no. 11 (June 15, 2007): 680–88. http://dx.doi.org/10.1142/s0219030307000729.
Full textAbstract:
Australia — Glaxo Cervical Cancer Vaccine Approved in Australia. Australia — Ten Million Dollar Grant to Establish Australian Mammalian Cell Production Facility. Australia — AgResearch and CSIRO Plant Industry Collaborate. China — Bird Flu Continues to be Public a Health Threat in China. China — China to Regularly Probe Drug Market. China — China and Cuba Set Up Joint Biotech Venture. China — GlaxoSmithKline to Set up a Drug Research Center in China. China — China Commited to Control the Spread of HIV. China — China Implements Tight Control Ordered over Assisted Reproductive Technology. India — OPPI to Adopt Marketing Code for Medicines. Indonesia — Indonesia Says US Critics Helped Push WHO to Change Virus-Sharing System. Indonesia — Indonesia Hands Out Kits to Fight Bird Flu. Japan — Kobe Team Succeeds in Mass Cultivation of Stem Cells. Malaysia — Bird Flu in Selangor "Confined to Three Villages". Malaysia — Polartechnics' Cervical Screening System Goes to Malaysia. New Zealand — Ryman Donates US$120 000 to Medical Research. New Zealand — New Zealand Establishes First Private Radiotherapy Center in Auckland. New Zealand — New Zealand Offers R&D Tax Incentives. Singapore — Singapore Steps up Fight against Dengue. South Korea — Korea Opens First Proton Radiotherapy Center. South Korea — Korean Yuyu Inc Files Patent Litigation against Merck. South Korea — South Korea Slaughters Thousands of Pigs to Stem Spread of Bird Flu. Thailand — Cancer — Next Priority in Pharma War. Thailand — Population and Community Development Association (PDA) of Thailand Receives 2007 Gates Award. Thailand — Eisai Seeks Thailand's Approval for Gasmotin. Vietnam — Bird Flu Survivors' Antibodies Effective.
43
"BioBoard." Asia-Pacific Biotech News 10, no. 18 (September 30, 2006): 999–1007. http://dx.doi.org/10.1142/s0219030306001534.
Full textAbstract:
Australia — ASIC Sues Citrofresh. Australia — IDT's Blackman, Mattick Awarded "Science Oscars". Australia — Medical Fellowship in Honor of Zhou. Australia — Stem Cell Sciences Joins European Program. China — Johnson & Johnson Breaks Ground for the Biggest Base in Asia. China — Beijing Sinovac Biotech Seeks Volunteers for 2nd Bird Flu Vaccine Trial. China — CAS Establishes Five More Research Institutes. China — China to Increase Support for Drug Research and Production. China — Chinese Government Reduces Drug Price. Hong Kong — Shaw Prize for Six Scientists. India — India Ayurvedic Medicine Gives Hope to Alzheimer. India — Indian Drug Maker Buys DHA. Japan — Takeda's Actos Reduces Risk of Second Stroke. Malaysia — KL's New Initiatives for its Biotech Industry. Singapore — Professor Philip Ingham to Boost Singapore's Biomedical Drive. Singapore — Health Agreements Between Singapore and Chinese Companies. Singapore — Biosensors Confident of Approval for its Stent. Singapore — More Drug Companies Conducting Trials in Singapore. Singapore — New Breed of Doctors to be Trained at Duke-NUS Medical School. Taiwan — Taiwan Hosts International Biologics and Vaccine Conference. Taiwan — Taiwan and Vietnam Sign Agreement to Fight Disease. Taiwan — Taiwan to Invest NT$300 million for Biofuel Research Efforts. Taiwan — Taiwan's Medical Sensor Breakthrough. Taiwan — HIV Vaccine Trials in Taiwan. Others — Vietnam Prepares for Potential Bird Flu Outbreaks Among Humans. Others — AIDS Meeting Urged to Rethink Prevention Strategy. Others — WHO Warns About Drug-Resistant TB.
44
"General Information and Statistics." Asia-Pacific Biotech News 05, no. 17 (August 20, 2001): 408–12. http://dx.doi.org/10.1142/s021903030100074x.
Full textAbstract:
Eastern China's Zhejiang Province to Set Up Biomedical Park. India's Wheat Exports Hit New Lows. Steady Development of China's Pharmaceutical Industry. Australia's New AIDS Vaccine to Enter Human Trials Next Year. Singapore Continues to Face Shortage of Nurses. More Chinese Couples Hope to Store Embryos for Future Use. Bioscience Symposium Opens in Taiwan.
45
"BioBoard." Asia-Pacific Biotech News 10, no. 14 (July 30, 2006): 707–15. http://dx.doi.org/10.1142/s0219030306001224.
Full textAbstract:
Australia to Lead a Global Project to Document Human Variation and Transformation Genetic Health. EvoGenix Nets $1.66 m Grant for Cancer Work. First Live Porcine Vaccine in Australia. PharmAust Collaborates with Bristol Pharma Australia. Agricultural Biotechnology International Conference in Melbourne. Stanford Signs Pact to Provide Online Health Information to China. Lonza Increases Stakes in China. China Invests in International Traditional Chinese Medicine Programs. China's Science Ministry Reforms to Prevent Misconduct. China Harnesses Brain Power for Life Science Industry. Chinese Society of Biotechnology Holds Annual Conference. TWAS Prizes in Biology — China and Brazil. China to Reform Biotech Policies. Bird Flu News in Indonesia. Hong Kong University Vice—Chancellor Lap-Chee Tsui Appointed as an Honor Professor of Zhejiang University. Australia and Korea Fishing for Synergies. Top Indian Health Institute Sacks its Director. LabVantage India Eyeing the Domestic Pharma & Healthcare Market. India's Panacea Biotec Signs Deal with Indonesian PT Bio Pharma. International Congress Held in India. Kyowa Hakko Kogyo to Expand its Fuji Plant and Accelerate R&D for Antibody Drugs. Crucell Licenses Cell Line Technology to Japanese Firm. Malaysia's Biotechnology Asia 2006 will Gather Global Industry Players, Researchers and Entrepreneurs. New Zealand Launch Technology Partnership Programs. CombinatoRx Receives Infectious Disease Research Grant from Singapore's EDB. Singapore's RIEC Allocates $1.4 billion for Three Research Programs. ITRI and UK's Sanger Institute Sign Research Collaboration MOU. Warren Buffet Pledges Most of his Fortune to Gates Foundation.
46
"Bioboard." Asia-Pacific Biotech News 12, no. 11 (September 2008): 5–19. http://dx.doi.org/10.1142/s0219030308000700.
Full textAbstract:
AUSTRALIA — Allogenic Stem Cells Effectively Treat Eye Diseases AUSTRALIA — Leukemia Breakthrough in Australia AUSTRALIA — A$20 Million for ICT Innovation in Healthcare AUSTRALIA — Impact of “Silent” Osteoporosis on Australians AUSTRALIA — Bacteria that Eat Cancer-causers Found AUSTRALIA — New Therapy for HIV Treatment CHINA — Chinese SFDA Approves Helicon's ReCell® Concept and Kit — Skin Regeneration Concept and Device CHINA — Research on Breast Cancer Stem Cells Offers Hope for Vaccine CHINA — Infectious Intestinal Disease on Rise in North-east China, Causing 3 Deaths CHINA — Global Stem Cell Forum in China Showcases Cutting-edge Research, Focuses on New Findings for IPS Cells INDONESIA — Samsung Group to Develop Indonesian Biodiesel INDIA — Indian Researchers on Way to Creating Vital Part of Human Eye INDIA — Hyundai Motor Launches Rural Mobile Health Clinic INDIA — Varadachari Implants New Life with Bio-release Micronutrients INDIA — Siemens to Make Nuclear Medicines at Indian Plants INDIA — Milestone Disc Replacement Surgery (4-level) Performed for the First Time in Asia at Artemis Health Institute INDIA — Transasia Announces All India Launch of Erba Den-Go to Detect Dengue INDIA — Biotech Sector Grows by 20% INDIA — U.S., Europe, Australia to Jointly Inspect Indian Drug Factories INDIA — Chennai Gets India's First Heart Implant Training Centre JAPAN — MDS Pharma Opens New Facility in Japan SINGAPORE — New Heart Disease Drug with Fewer Side Effects Available in Singapore SINGAPORE — A*STAR and Oxford University Agreement Boosts Doctoral Training for A*STAR Scholars TAIWAN — Biotech Sees Major Industry Changes VIETNAM — Herbal Drug Offers Hope for Addicts
47
"Bioboard." Asia-Pacific Biotech News 13, no. 05 (May 2009): 5–23. http://dx.doi.org/10.1142/s0219030309000299.
Full textAbstract:
AUSTRALIA – Minimizing Spread of Deadly Hendra Virus. AUSTRALIA – Breakthrough High Blood Pressure Treatment Trial Down Under. AUSTRALIA – Australia Sees Rise in Newborn Withdrawal Syndrome. CHINA – CAS, Hong Kong University Set Up Joint Lab of Natural Medicine. CHINA – Chinese Researchers Discover 20 Essential Genes in Polyoxin. CHINA – China Aims to Lead Asia's Stem Cell R&D. CHINA – China Rural Areas on High Alert for Hand, Foot and Mouth Disease. CHINA – Hepatitis Infects 64 at China Hospital. CHINA – China's Colorectal Cancer Drug Market will More Than Double by 2012. CHINA – Critical Gene for Enhancing China's Super Rice Yield Identified. CHINA – Chinese Scientists say New Discovery May Yield Clue to Cure Human Infertility. HONG KONG – Compound to Fight Bird Flu Identified. INDIA – Yashoda Cancer Institute Treats First Patient In India Using RapidArc Radiotherapy Technology. INDIA – Indian Pharma Industry May Gain $18.4 bn from Global Market. INDIA – Philips to Make India Hub for Medical Equipment Manufacturing. JAPAN – Herbal Medicines to Treat Gastrointestinal Disease. SINGAPORE – Tetravalent Dengue Vaccine Trial in Singapore. SINGAPORE – Minimally Invasive Robot-Assisted Surgeries for Heart Patients. SINGAPORE – US-Based Company Launches Singapore Doctor Search Site for Medical Travelers. SINGAPORE – Genetic Research: Time for a rethink? SINGAPORE – Test Kits to be Licensed. SINGAPORE – Local Team Develops Method to Predict Heart Disease. SINGAPORE – Consumer Genetic Tests – A Cause for Worry? SINGAPORE – S'pore Firm's Test Kit Joins the Fight. SINGAPORE – Singapore Gives New Hope To The Blind. SINGAPORE – Singapore and Korea Research Institutes Embark on Landmark Collaboration for Breakthroughs in Micro and Nanotechnology. SOUTH KOREA – Institute Develops Cheap Cholera Vaccine. TAIWAN – Herbal Substance Developed for Cardiovascular Disease. TAIWAN – Prototype of Household Breast Cancer Detector Unveiled. TAIWAN – Breakthrough in New Diabetes Drug.
48
"BioBoard." Asia-Pacific Biotech News 11, no. 03 (February 15, 2007): 129–38. http://dx.doi.org/10.1142/s0219030307000158.
Full textAbstract:
Australia — New Cooperative Research Center for Cancer Therapeutics in Melbourne. Australia — WEHI Collaborates with Genentech to Develop New Cancer Drugs. Australia — Australia Prepares to Vaccinate its Entire Population Against Bird Flu. China — China Revokes Licenses of 160 Drug Firms. China — Three More National Laboratories to be Set up at CAS. China — Covance Expands Operations in China. China — CAS Launches a New Round of Academician Selection with Strict Procedures. China — China Slashes Cost of Overpriced Drugs. China — New Diabetic Drug Manufactured in Shanghai. Japan — Japan Confirms 32nd Mad Cow Case. Japan — New Bird Flu Outbreak Suspected in Japan. Indonesia — Indonesia to Declare Bird Flu a National Disaster. Indonesia — Baxter Collaborates with the Indonesian Government. Indonesia — Indonesia Develops a Bird Flu Vaccine. India — India to Carry Out First Multi-centric Clinical Trial with Stem Cells. India — Lotus Labs and Labindia Team Up to Build a Clinical Research Academy. India — Bangalore to Build Knowledge City. India — Indian Companies to Bid for Merck's Generics Business. India — India and Croatia Pledge One million Euros for Scientific Research. India — India to Lead in Global Stem Cell Market by 2010. India — Biotech Leaders Receive Indian Government Awards. Malaysia — Malaysia Opens a New Laboratory for Hazardous Disease Research. Philippines — Philippines Bans Imports of Live Birds and Poultry from Japan. Singapore — Singapore Keeping up Vigilance Against Infectious Diseases. Singapore — Singapore Health Ministry Considering Legislation on Biomedical Research. Singapore — TNT Appoints Onno Boots as South East Asia's Regional Managing Director. South Korea — South Korea Aims to Become Top 10 Science Nation by 2010. Taiwan — Taiwan Works on Bird Flu Vaccine. Taiwan — Taiwan Introduces World's First DNA chip. Thailand — Bird Flu Strikes in Thailand Again. Thailand — Thai Pharma Industry Against Thai Government's Decision to Produce Generic Drugs.
49
Mizzi, Rachel, Verlaine J. Timms, Marian L. Price-Carter, Milan Gautam, Richard Whittington, Cord Heuer, Patrick J. Biggs, and Karren M. Plain. "Comparative Genomics of Mycobacterium avium Subspecies Paratuberculosis Sheep Strains." Frontiers in Veterinary Science 8 (February 15, 2021). http://dx.doi.org/10.3389/fvets.2021.637637.
Full textAbstract:
Mycobacterium avium subspecies paratuberculosis (MAP) is the aetiological agent of Johne's disease (JD), a chronic enteritis that causes major losses to the global livestock industry. Further, it has been associated with human Crohn's disease. Several strains of MAP have been identified, the two major groups being sheep strain MAP, which includes the Type I and Type III sub-lineages, and the cattle strain or Type II MAP lineage, of which bison strains are a sub-grouping. Major genotypic, phenotypic and pathogenic variations have been identified in prior comparisons, but the research has predominately focused on cattle strains of MAP. In countries where the sheep industries are more prevalent, however, such as Australia and New Zealand, ovine JD is a substantial burden. An information gap exists regarding the genomic differences between sheep strain sub-lineages and the relevance of Type I and Type III MAP in terms of epidemiology and/or pathogenicity. We therefore investigated sheep MAP isolates from Australia and New Zealand using whole genome sequencing. For additional context, sheep MAP genome datasets were downloaded from the Sequence Read Archive and GenBank. The final dataset contained 18 Type III and 16 Type I isolates and the K10 cattle strain MAP reference genome. Using a pan-genome approach, an updated global phylogeny for sheep MAP from de novo assemblies was produced. When rooted with the K10 cattle reference strain, two distinct clades representing the lineages were apparent. The Australian and New Zealand isolates formed a distinct sub-clade within the type I lineage, while the European type I isolates formed another less closely related group. Within the type III lineage, isolates appeared more genetically diverse and were from a greater number of continents. Querying of the pan-genome and verification using BLAST analysis revealed lineage-specific variations (n = 13) including genes responsible for metabolism and stress responses. The genetic differences identified may represent important epidemiological and virulence traits specific to sheep MAP. This knowledge will potentially contribute to improved vaccine development and control measures for these strains.
50
"BioBoard." Asia-Pacific Biotech News 10, no. 12 (June 30, 2006): 643–50. http://dx.doi.org/10.1142/s0219030306000905.
Full textAbstract:
Ian Frazer Named Australian of the Year. Further Funding For Australian Medical Research. Blockbuster Gardisil Approved by FDA. Potential Ovarian Cancer Diagnostic Test on Trial in Melbourne. Seven Scientists Elected as CAS Foreign Members. CAS and University of Tokyo Set up Joint Laboratories. AstraZeneca to Invest $100 million in China. Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) Partner with the Danish Pharmaceutical Company Lundbeck. Anti-flu Tamiflu Approved in China. China Develops New Bird Flu Vaccines. China Collaborates with WHO to Fight Infectious Diseases. Apollo Hospitals Eyes Acquisition in South-East Asia. India Opens New Free AIDS Therapy Centers. Ranbaxy Faces Criminal Charges for Price-fixing of Antibiotics and Warfarin. Nobel Laureate Norman E. Borlaug Calls for Gene Revolution in India. Carlyle Asia Growth Partners III Raises US$668 Million to Support Emerging Asian Business Leaders with Expansion Capital. Kyoto University and Summit Pharmaceuticals International Corp Collaborate. Grain Crisis Looms in Japan. University Student Named New Zealand's Young Scientist of the Year. New Boost in New Zealand Biotech Industry. HP and A*STAR to Open $30 Million R&D Lab. A*STAR to Collaborate with Australian National University. Singapore's BAC Announces Biomedical Research Data to be Off-limits to Third Parties.